Guardant Health (GH) traded higher Friday, April 24, 2026, with the move appearing tied to pre-earnings positioning ahead of its scheduled first-quarter 2026 results after the close on May 7, 2026. With no same-day company filing or fresh clinical readout surfacing in widely distributed channels, the tape action looked driven by anticipation of near-term updates on Shield commercialization and overall 2026 execution.

The company’s upcoming May 7 earnings report is the next clear catalyst, as investors look for evidence that Shield’s launch trajectory is translating into sustained screening volumes and revenue. Guardant has highlighted scaling initiatives for Shield, and the market is likely using the next report to gauge whether expanding access and ordering workflows are converting into repeatable growth.

Guardant’s Shield blood-based colorectal cancer screening test became widely accessible for physician ordering through Quest Diagnostics’ national network on March 10, 2026, enabling ordering via existing Quest accounts and EHR connectivity and leveraging Quest’s patient service centers and in-office phlebotomy footprint. That kind of distribution upgrade can tighten the path from physician intent to completed blood draw, which investors often translate into better adoption curves for screening products.